We confirmed the presence of mutations in genes previously reported in BL literature[18,19,28] (Fig 3A–3C and S4 Table), including MYC in 10/20 (50%), DDX3X in 7/20 (35%), ID3 in 6/20 (30%), ARID1A in 5/20 (25%), RHOA in 4/20 (20%), TCF3 and TP53 in 3/20 (15%), CCND3 in 1/20 (5%) of the cases. This evidence concerns the gene TP53 and Burkitt lymphoma.